Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 2001 Jun 15;356(Pt 3):813–819. doi: 10.1042/0264-6021:3560813

Highly sensitive and selective fluorescence assays for rapid screening of endothelin-converting enzyme inhibitors.

N Luciani 1, H de Rocquigny 1, S Turcaud 1, A Romieu 1, B P Roques 1
PMCID: PMC1221908  PMID: 11389689

Abstract

The highly potent vasoconstrictor peptide endothelin (ET) is generated from an inactive precursor, big endothelin (bET), by endothelin-converting enzyme (ECE). ECE is a phosphoramidon-sensitive zinc metallopeptidase, which is closely related to neprilysin (neutral endopeptidase). It is possible that compounds which inhibit the formation of ET may be used as new drugs for the treatment of cardiovascular diseases. Such an approach requires a fast, simple and selective assay to measure ECE activity, allowing rapid screening of inhibitors. We describe here two new ECE substrates based on the concept of 'intramolecularly quenched fluorescence' which may fulfill this aim. One, S(1) [Pya(21)-Nop(22)-bET-1(19--35)], is the (19--35) fragment of the natural peptide big-ET-1(1--38), which is modified by introducing the fluorescent amino acid, pyrenylalanine (Pya), in position 21 and a quencher, p-nitrophenylalanine (Nop), in position 22. The second substrate (S(2)) is a small peptide, Ac-Ser-Gly-Pya-Lys-Ala-Phe-Ala-Nop-Gly-Lys-NH(2), from a biased substrate peptide library. The recombinant, hECE-1c, cleaved both Pya(21)-Nop(22)-bET-1(19--35) and the natural substrate selectively between residues 21 and 22, whereas cleavage occurred between alanine and phenylalanine in the small peptide. In both cases, this generated intense fluorescence emission. The synthesis and kinetic parameters of these substrates are described. These assays, which can be used directly on tissue homogenates, are the most sensitive and selective described to date for ECE, and are easily automated for a high-throughput screening of inhibitors.

Full Text

The Full Text of this article is available as a PDF (165.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aubry M., Berteloot A., Beaumont A., Roques B. P., Crine P. The use of a monoclonal antibody for the rapid purification of kidney neutral endopeptidase ("enkephalinase") solubilized in octyl glucoside. Biochem Cell Biol. 1987 Apr;65(4):398–404. doi: 10.1139/o87-050. [DOI] [PubMed] [Google Scholar]
  2. Carmel A., Kessler E., Yaron A. Intramolecularly-quenched fluorescent peptides as fluorogenic substrates ofleucine aminopeptidase and inhibitors of clostridial aminopeptidase. Eur J Biochem. 1977 Mar 1;73(2):617–625. doi: 10.1111/j.1432-1033.1977.tb11357.x. [DOI] [PubMed] [Google Scholar]
  3. Cheng Y., Prusoff W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973 Dec 1;22(23):3099–3108. doi: 10.1016/0006-2952(73)90196-2. [DOI] [PubMed] [Google Scholar]
  4. Coric P., Turcaud S., Meudal H., Roques B. P., Fournie-Zaluski M. C. Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors. J Med Chem. 1996 Mar 15;39(6):1210–1219. doi: 10.1021/jm950590p. [DOI] [PubMed] [Google Scholar]
  5. Hoang M. V., Turner A. J. Novel activity of endothelin-converting enzyme: hydrolysis of bradykinin. Biochem J. 1997 Oct 1;327(Pt 1):23–26. doi: 10.1042/bj3270023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Huggins J. P., Pelton J. T., Miller R. C. The structure and specificity of endothelin receptors: their importance in physiology and medicine. Pharmacol Ther. 1993;59(1):55–123. doi: 10.1016/0163-7258(93)90041-b. [DOI] [PubMed] [Google Scholar]
  7. Inoue A., Yanagisawa M., Kimura S., Kasuya Y., Miyauchi T., Goto K., Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A. 1989 Apr;86(8):2863–2867. doi: 10.1073/pnas.86.8.2863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Johnson G. D., Stevenson T., Ahn K. Hydrolysis of peptide hormones by endothelin-converting enzyme-1. A comparison with neprilysin. J Biol Chem. 1999 Feb 12;274(7):4053–4058. doi: 10.1074/jbc.274.7.4053. [DOI] [PubMed] [Google Scholar]
  9. Kiowski W., Sütsch G., Hunziker P., Müller P., Kim J., Oechslin E., Schmitt R., Jones R., Bertel O. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 1995 Sep 16;346(8977):732–736. doi: 10.1016/s0140-6736(95)91504-4. [DOI] [PubMed] [Google Scholar]
  10. Masaki T. Possible role of endothelin in endothelial regulation of vascular tone. Annu Rev Pharmacol Toxicol. 1995;35:235–255. doi: 10.1146/annurev.pa.35.040195.001315. [DOI] [PubMed] [Google Scholar]
  11. Ohnaka K., Takayanagi R., Nishikawa M., Haji M., Nawata H. Purification and characterization of a phosphoramidon-sensitive endothelin-converting enzyme in porcine aortic endothelium. OFF. J Biol Chem. 1993 Dec 15;268(35):26759–26766. [PubMed] [Google Scholar]
  12. Pantoliano M. W., Holmquist B., Riordan J. F. Affinity chromatographic purification of angiotensin converting enzyme. Biochemistry. 1984 Feb 28;23(5):1037–1042. doi: 10.1021/bi00300a036. [DOI] [PubMed] [Google Scholar]
  13. Patel T. R., Galbraith S. L., McAuley M. A., Doherty A. M., Graham D. I., McCulloch J. Therapeutic potential of endothelin receptor antagonists in experimental stroke. J Cardiovasc Pharmacol. 1995;26 (Suppl 3):S412–S415. [PubMed] [Google Scholar]
  14. Roques B. P., Noble F., Daugé V., Fournié-Zaluski M. C., Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev. 1993 Mar;45(1):87–146. [PubMed] [Google Scholar]
  15. Saito Y., Nakao K., Mukoyama M., Imura H. Increased plasma endothelin level in patients with essential hypertension. N Engl J Med. 1990 Jan 18;322(3):205–205. doi: 10.1056/nejm199001183220315. [DOI] [PubMed] [Google Scholar]
  16. Schechter I., Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun. 1967 Apr 20;27(2):157–162. doi: 10.1016/s0006-291x(67)80055-x. [DOI] [PubMed] [Google Scholar]
  17. Schmidt M., Kröger B., Jacob E., Seulberger H., Subkowski T., Otter R., Meyer T., Schmalzing G., Hillen H. Molecular characterization of human and bovine endothelin converting enzyme (ECE-1). FEBS Lett. 1994 Dec 19;356(2-3):238–243. doi: 10.1016/0014-5793(94)01277-6. [DOI] [PubMed] [Google Scholar]
  18. Schweizer A., Valdenaire O., Nelböck P., Deuschle U., Dumas Milne Edwards J. B., Stumpf J. G., Löffler B. M. Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localizations. Biochem J. 1997 Dec 15;328(Pt 3):871–877. doi: 10.1042/bj3280871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Shimada K., Matsushita Y., Wakabayashi K., Takahashi M., Matsubara A., Iijima Y., Tanzawa K. Cloning and functional expression of human endothelin-converting enzyme cDNA. Biochem Biophys Res Commun. 1995 Feb 15;207(2):807–812. doi: 10.1006/bbrc.1995.1258. [DOI] [PubMed] [Google Scholar]
  20. Shimada K., Takahashi M., Ikeda M., Tanzawa K. Identification and characterization of two isoforms of an endothelin-converting enzyme-1. FEBS Lett. 1995 Sep 4;371(2):140–144. doi: 10.1016/0014-5793(95)00886-e. [DOI] [PubMed] [Google Scholar]
  21. Shimada K., Takahashi M., Tanzawa K. Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J Biol Chem. 1994 Jul 15;269(28):18275–18278. [PubMed] [Google Scholar]
  22. Shimada K., Takahashi M., Turner A. J., Tanzawa K. Rat endothelin-converting enzyme-1 forms a dimer through Cys412 with a similar catalytic mechanism and a distinct substrate binding mechanism compared with neutral endopeptidase-24.11. Biochem J. 1996 May 1;315(Pt 3):863–867. doi: 10.1042/bj3150863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Soleilhac J. M., Cornille F., Martin L., Lenoir C., Fournié-Zaluski M. C., Roques B. P. A sensitive and rapid fluorescence-based assay for determination of tetanus toxin peptidase activity. Anal Biochem. 1996 Oct 1;241(1):120–127. doi: 10.1006/abio.1996.0385. [DOI] [PubMed] [Google Scholar]
  24. Suzuki N., Matsumoto H., Kitada C., Kimura S., Miyauchi T., Fujino M. A sandwich-type enzyme immunoassay to detect immunoreactive big-endothelin-1 in plasma. J Immunol Methods. 1990 Mar 9;127(2):165–170. doi: 10.1016/0022-1759(90)90065-4. [DOI] [PubMed] [Google Scholar]
  25. Takahashi M., Matsushita Y., Iijima Y., Tanzawa K. Purification and characterization of endothelin-converting enzyme from rat lung. J Biol Chem. 1993 Oct 5;268(28):21394–21398. [PubMed] [Google Scholar]
  26. Valdenaire O., Lepailleur-Enouf D., Egidy G., Thouard A., Barret A., Vranckx R., Tougard C., Michel J. B. A fourth isoform of endothelin-converting enzyme (ECE-1) is generated from an additional promoter molecular cloning and characterization. Eur J Biochem. 1999 Sep;264(2):341–349. doi: 10.1046/j.1432-1327.1999.00602.x. [DOI] [PubMed] [Google Scholar]
  27. Valdenaire O., Rohrbacher E., Mattei M. G. Organization of the gene encoding the human endothelin-converting enzyme (ECE-1). J Biol Chem. 1995 Dec 15;270(50):29794–29798. doi: 10.1074/jbc.270.50.29794. [DOI] [PubMed] [Google Scholar]
  28. Xu D., Emoto N., Giaid A., Slaughter C., Kaw S., deWit D., Yanagisawa M. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell. 1994 Aug 12;78(3):473–485. doi: 10.1016/0092-8674(94)90425-1. [DOI] [PubMed] [Google Scholar]
  29. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988 Mar 31;332(6163):411–415. doi: 10.1038/332411a0. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES